Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences?

Annals of Surgical Oncology

Volumn 7, Issue 2, 2000, Pages 114-119

  Shen, Perry ^a   Guenther, J Michael ^a   Wanek, Leslie A ^a   Morton, Donald L ^a,b  

^a SAINT JOHN'S HEALTH CENTER   (United States)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Disease free interval; Lymph node dissection; Melanoma; Recurrence

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHILD; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PROGNOSIS;

EID: 0034070390     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-000-0114-x     Document Type: Article

References (19)

1. Epstein E, Bragg AK. Curability of melanoma: a 25-year retrospective study. Cancer 1980;46:818-21.
2. Callaway MP, Briggs JC. The incidence of late recurrence (greater than 10 years): an analysis of 536 consecutive cases of cutaneous melanoma. Br J Surg 1989;42:46-9.
3. Levy F., Silverman MK, Vossaert KA. Late recurrence of malignant melanoma: a report of five cases, a review of the literature and a study of associated factors. Melanoma Res 1991;1:63-7.
4. Schultz S, Kane M, Roush R, et al. Time to recurrence varies inversely with thickness in clinical stage I cutaneous melanoma. Surg Gynecol Obstet 1990;171:393-7.
5. Shaw HM, Beattie CW, McCarthy WH, Milton GW. Late relapse from cutaneous stage I malignant melanoma. Arch Surg 1985;120: 1155-9.
6. Briele HA, Beattie CW, Ronan SG, Chandhuri PK, Das Gupta TK. Late recurrence of cutaneous melanoma. Arch Surg 1983;118: 800-3.
7. Cascinelli N, Morabito A, Bufalino R, et al. Prognosis of stage I melanoma of the skin. Int J Cancer 1980;26:733-39.
8. Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA. A multifactorial analysis of melanoma: prognostic and histopathological features comparing Clark's and Breslow staging methods. Ann Surg 1978;188:732-42.
9. Day CL Jr, Sober AJ, Kopf AW. A prognostic model for clinical stage I melanoma of the upper extremity: the importance of anatomic subsites in predicting recurrent disease. Ann Surg 1981;193: 436-40.
10. Yarnold JR, Cochrane JP. Malignant melanoma: significance of disease-free interval. Br J Radial 1980;53:1068-70.
11. O'Donnell M, Silove D, Wakefield D. Current perspectives on immunology and psychiatry. Aust NZJ Psychiatry 1988;22:366-82.
12. Morton DL, Wen D-R, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
13. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998;351:793-6.
14. Balch CM, Ross M, Soong S-J, Harrison R. Long-term results of a prospective, randomized trial involving elective regional lymph node dissection in patients with intermediate thickness melanomas. Ann Surg Oncol 2000;7:87-97.
15. DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles & Practice of Oncology. Philadelphia: Lippincott-Raven, 1997.
16. Crowley NJ, Seigler HF. Late recurrence of malignant melanoma. Ann Surg 1990;212:173-77.
17. Tsao H, Cosimi AB, Sober AJ Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 1997;79:2361-70.
18. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-83.
19. Essner R, Conforti A, Kelley MC, et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol 1999;6:442-9.